Katherine  Goodrich net worth and biography

Katherine Goodrich Biography and Net Worth

Kate is a distinguished healthcare leader whose career has driven system-wide transformation in clinical policy, value-based care and health equity. Most recently, she served as Chief Medical Officer of Humana, where she provided executive clinical leadership for both the insurance and CenterWell businesses, guiding physician engagement, healthcare research and social-impact initiatives. She previously served as Senior Vice President for Clinical Analytics and Trends within Humana’s Clinical Solutions organization, where she was responsible for delivering business analytics and rapid-learning models designed to improve outcomes at lower cost.

Prior to Humana, Kate spent more than a decade at the Centers for Medicare & Medicaid Services (CMS), where she was both the Director of the Center for Clinical Standards and Quality (CCSQ) and the Chief Medical Officer. In these roles, she shaped national policies to improve quality, safety and transparency across the US healthcare system.

For more than 25 years, Kate has also served on the faculty of the George Washington University Medical Center (GWUMC), where she continues to practice as a hospitalist and professor of medicine. She currently serves on the boards of the National Quality Forum and the Institute for Accountable Care. Kate earned her MD from Louisiana State University School of Medicine and a master’s degree in health services research from Yale University.

What is Katherine Goodrich's net worth?

The estimated net worth of Katherine Goodrich is at least $141.04 thousand as of June 15th, 2026. Goodrich owns 2,233 shares of Tarsus Pharmaceuticals stock worth more than $141,036 as of June 19th. This net worth estimate does not reflect any other assets that Goodrich may own. Learn More about Katherine Goodrich's net worth.

How do I contact Katherine Goodrich?

The corporate mailing address for Goodrich and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected]. Learn More on Katherine Goodrich's contact information.

Has Katherine Goodrich been buying or selling shares of Tarsus Pharmaceuticals?

Within the last three months, Katherine Goodrich has sold $183,384.32 in shares of Tarsus Pharmaceuticals stock. Most recently, Katherine Goodrich sold 2,954 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.08, for a transaction totalling $183,384.32. Following the completion of the sale, the director now directly owns 2,233 shares of the company's stock, valued at $138,624.64. Learn More on Katherine Goodrich's trading history.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Katherine Goodrich (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), William Link, PhD (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, insiders at the sold shares 24 times. They sold a total of 161,754 shares worth more than $10,534,747.29. The most recent insider tranaction occured on June, 16th when insider Jeffrey S Farrow sold 14,396 shares worth more than $877,436.20. Insiders at Tarsus Pharmaceuticals own 9.6% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.

Information on this page was last updated on 6/16/2026.

Katherine Goodrich Insider Trading History at Tarsus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2026Sell2,954$62.08$183,384.322,233View SEC Filing Icon  
See Full Table

Katherine Goodrich Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Katherine Goodrich's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $63.16
Low: $62.37
High: $64.24

50 Day Range

MA: $63.35
Low: $57.41
High: $73.81

2 Week Range

Now: $63.16
Low: $38.51
High: $85.25

Volume

402,143 shs

Average Volume

562,502 shs

Market Capitalization

$2.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49